Looking for Investment, Acquisition, Partnerships or Collaborations?
this event has run!
In 2024, having hosted AbbVie, AZ, Biogen, J&J, Merck, Sanofi, Regeneron, Otsuka, and UCB, the Autoimmunity Pharma & Biotech Partnering Summit guaranteed 30-minute, in-person meetings, to foster scientific partnerships across targeted cell depletion and immune tolerance.
Having helped both biotech and pharma cut through the noise to enhance portfolios, drive external collaboration, and promote creative partnerships across early-stage innovation; this unique initiative was an intensely valuable 48 hours for business development across immunology.
2024 EVENT IN NUMBERS
attending companies across modalities so pharma could decide which horse to back in this quickly evolving space
big pharma leads across business development, search and evaluation, immunology research and venture gave the best, most comprehensive opportunity to meet the full teams assessing due diligence and asset synergy
meetings bookable via the partnering portal for efficient and high yielding conversations between decision makers
alignment on interests and intentions, increasing the surface area for synergy in research and collaboration goals
Testimonials
Key Figures from Partnering Series
meetings through the partnering portal
acceptance rate of meetings, versus 11% industry standard
total attendees, including: 23 pharma, 65 biotech
companies, including: 16 pharma, 58 biotech, 4 investors
C-level, 57% Vice President or Above, 94% Director or above